All In Biotech

Drug Trial Radar · NCT06854653

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Jan 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Prescient Therapeutics, Ltd.Industry
Sponsor type
Industry
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.

Conditions

  • CTCL

Interventions

  • PTX-100Drug

    Peptidomimetic inhibitor of GGTase 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the efficacy of PTX-100 as determined by ORR.Time frame: 18 months from day of first treatment until disease progression, unacceptable toxicity, participant or Investigator decision.

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Cente

    Duarte, California · Recruiting

  • University of California Irvine

    Irvine, California · Completed

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Rochester Skin Lymphoma Medical Group. PLLC

    Rochester, New York · Recruiting

  • Virginia Commonwealth University Massey Comprehensive Cancer Cente

    Richmond, Virginia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Epworth Healthcare

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • CHU de Bordeaux - Hopital Saint André

    Bordeaux, Bordeaux, France · Not yet recruiting

  • Hopital Saint Louis

    Paris, Île-de-France Region, France · Not yet recruiting

  • Hopital Lyon Sud

    Lyon, Pierre-Benite, France · Not yet recruiting

  • IRCCS Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi

    Bologna, Bologna, Italy · Recruiting

  • Universita degli Studi Di Brescia-Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    Brescia, Brescia, Italy · Recruiting

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)

    Milan, Milano, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.